About this trial

“20% of patients of childbearing age who receive ICIs for cancer will have a reduction in any reproductive parameter due to either reduced gametogenesis; autoantibody formation or endocrine dysfunction as a result of ICI therapy, identified within the first 2 years of ICI therapy.

This study will test this hypothesis by the assessment of AMH level, AFC, in females and sperm concentration, motility, morphology and anti-sperm antibodies in males at prespecified timepoints in the first 1-2 years post ICI therapy.”

Patient Profile

Where’s this trial being run?

Beaumont Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Number: 22-22
Full Title:

A prospective observational study investigating the impact of immune checkpoint inhibitors for cancer on fertility in males and females of childbearing age

Principal Investigator: Prof Jarushka Naidoo

Investigator Led Trial

Recruitment Started: Global: N/A
Ireland: Yes
Global Recruitment Target: N/A
Ireland Recruitment Target: 88 - Open until late 2024